替加环素联合头孢哌酮/舒巴坦治疗重症颅脑外伤患者耐药鲍氏不动杆菌感染的效果研究

The therapeutic effect study on tigecyline combined with cefoperazone/sulbactam in the treatment of Acinetobacter baumannii infections in patients with severe craniocerebral trauma

目的探讨头孢哌酮/舒巴坦联合替加环素治疗耐药鲍氏不动杆菌感染危重患者中的临床效果,为临床治疗提供参考依据。方法择取2013年1月-2015年6月重症颅脑外伤耐药鲍氏不动杆菌感染的患者300例,分为观察组和对照组,各150例;观察组使用头孢哌酮/舒巴坦联合替加环素治疗,对照组只给予头孢哌酮/舒巴坦治疗,比较两组患者的临床疗效,病原菌清除率和安全性,数据采用SPSS 16.0软件进行统计分析。结果患者治疗总有效率观察组为91.3%,明显高于对照组的75.3%;观察组耐药鲍氏不动杆菌清除率为70.7%,高于对照组的54.7%;不良反应发生率观察组为3.3%、对照组为10.7%,两组比较,差异均有统计学意义(P<0.05)。结论头孢哌酮/舒巴坦联合替加环素对重症颅脑外伤耐药鲍氏不动杆菌感染患者的治疗有良好效果,值得在临床上推广和应用。

OBJECTIVE To investigate the clinical effect of cefoperazone/sulbactam combined with tigecycline in traumatic brain injury patients with Acinetobacter baumannii infections so as to provide references for clinical treatments.METHODS Totally 300 A.baumannii infected patients with severe craniocerebral trauma admitted from Jan.2013 to Jun.2015 were selected and divided into observation group and control group with 150 cases each.The observation group received cefoperazone/sulbactam combined with tigecycline and the control group was only given cefoperazone/sulbactam.The clinical effect,pathogen clearance rate and safety of the two groups were compared.SPSS 16.0was explored to make statistical analysis.RESULTS The total effective rate of the observation group was 91.3%,which was significantly higher than that of the control group with 75.3%.The bacteria clearance rate of the observation group was 70.7%,higher than the control group of 54.7%.And the adverse reaction incidence of observation group was 3.3%,obviously lower than that of the control group with 10.7%.The differences were significant（P〈0.05）.CONCLUSIONCefoperazone/sulbactam combined with tigecycline can effectively treat A.baumannii infected patients with severe craniocerebral trauma and is worthy to be promoted and applied in clinical practices.